Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Elahere“
Suchtreffer
Begriffe & Kennungen
Elahere
Eintrag öffnenElahere · 4.1 Therapeutic indications · 1
Eintrag öffnenElahere · 4.3 Contraindications · 1
Eintrag öffnenElahere · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenElahere · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenElahere · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenElahere · 4.5 · Clinical drug-drug interaction studies with ELAHERE have not been conducted.
Eintrag öffnenElahere · 4.5 · DM4 is a CYP3A4 substrate. Concomitant use of ELAHERE with strong CYP3A4 inhibitors may increase unconjugated
Eintrag öffnenElahere · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenElahere · 4.8 Undesirable effects · 1
Eintrag öffnenElahere · 4.8 · 10 last follow-up, 0.3% (2/682) patients had ≥ Grade 3 ocular adverse events (1 patient with Grade 3 decreased
Eintrag öffnenElahere · 4.8 · Adverse reactions that most commonly led to dose reduction or dose delay were blurred vision (17%), keratopath
Eintrag öffnenElahere · 4.8 · Common Ocular discomfort6 Vascular disorders Common Hypertension Respiratory, thoracic and Very common Pneumon
Eintrag öffnenElahere · 4.8 · Description of selected adverse reactions
Eintrag öffnenElahere · 4.8 · Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare
Eintrag öffnenElahere · 4.8 · Ocular adverse reactions (grouped terms) occurred in 59% of patients with EOC treated with mirvetuximab soravt
Eintrag öffnenElahere · 4.8 · Ocular adverse reactions led to dose delays in 24% of patients, and dose reductions in 15% of patients. Ocular
Eintrag öffnenElahere · 4.8 · Ocular disorders
Eintrag öffnenElahere · 4.8 · Peripheral neuropathy
Eintrag öffnenElahere · 4.8 · Peripheral neuropathy (grouped terms) occurred in 36% of patients with EOC treated with mirvetuximab soravtans
Eintrag öffnen